KR830005220A - Preparation of new 3- (1-piperidinylalkyl) -4H-pyrido [1,2-a] pyrimidin-4-wan derivatives - Google Patents

Preparation of new 3- (1-piperidinylalkyl) -4H-pyrido [1,2-a] pyrimidin-4-wan derivatives Download PDF

Info

Publication number
KR830005220A
KR830005220A KR1019810001233A KR810001233A KR830005220A KR 830005220 A KR830005220 A KR 830005220A KR 1019810001233 A KR1019810001233 A KR 1019810001233A KR 810001233 A KR810001233 A KR 810001233A KR 830005220 A KR830005220 A KR 830005220A
Authority
KR
South Korea
Prior art keywords
group
hydrogen
compound
lower alkyl
general formula
Prior art date
Application number
KR1019810001233A
Other languages
Korean (ko)
Other versions
KR850000412B1 (en
Inventor
이. 제이. 케니스 루우도
세퍼스 씨. 마아텐스 죠오
Original Assignee
폴 아드리이안 쟌 쟈아젠
쟈아센 마파아슈우티가 엔. 부이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 폴 아드리이안 쟌 쟈아젠, 쟈아센 마파아슈우티가 엔. 부이. filed Critical 폴 아드리이안 쟌 쟈아젠
Publication of KR830005220A publication Critical patent/KR830005220A/en
Priority to KR1019840005210A priority Critical patent/KR850000413B1/en
Application granted granted Critical
Publication of KR850000412B1 publication Critical patent/KR850000412B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Abstract

내용 없음No content

Description

새로운 3-(1-피페리디닐알킬)-4H-피리도[1,2-a]피리미딘-4-완 유도체의 제조방법Preparation of new 3- (1-piperidinylalkyl) -4H-pyrido [1,2-a] pyrimidin-4-wan derivatives

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음As this is a public information case, the full text was not included.

Claims (11)

일반식,General Formula, 로 표시되는 3-[1-피페리딘일)알킬]-4H-피리도[1,2-a]피리미딘-4-완 유도체와 이것의 약제로 사용 가능한 산부가염으로 구성된 기로부터 선택된 화합물.A compound selected from the group consisting of 3- [1-piperidinyl) alkyl] -4H-pyrido [1,2-a] pyrimidin-4-wan derivatives represented by &lt; RTI ID = 0.0 &gt; and acid addition salts &lt; / RTI &gt; 이 식에서 : R1과 R2는 수소, 저급알킬, 저급알킬옥시, 할로 및 트리플루오로메틸로 부터 각각 독자적으로 선택된 것이고;Wherein R 1 and R 2 are each independently selected from hydrogen, lower alkyl, lower alkyloxy, halo and trifluoromethyl; R3는 수소, 저급알킬과 아릴로 구성된 기로부터 선택된 멤버이다;R 3 is a member selected from the group consisting of hydrogen, lower alkyl and aryl; Alk는 저급알킬렌 라디칼이다;Alk is a lower alkylene radical; R은 피페리딘 고리의 2-, 3-4 또는 4-위치에서 수소, 저급알킬, 히드록시, 저급알킬옥시 및 히드록시메틸로 구성된 기로부터 선택된 멤버이다;R is a member selected from the group consisting of hydrogen, lower alkyl, hydroxy, lower alkyloxy and hydroxymethyl at the 2-, 3-4 or 4-position of the piperidine ring; X는 X is >C=NOH 및 >C=N-NH2로 구성된 기로부터 선택된 멤버인데, 이중 Ra는 수소 또는 저급알킬이고 q는 정수 2 또는 3이다; 그리고A member selected from the group consisting of> C = NOH and> C = N-NH 2 , wherein R a is hydrogen or lower alkyl and q is an integer 2 or 3; And Ar은 아릴인데, 이 아릴은 페닐, 치환된 페닐, 티에닐, 푸란일 및 피리딘일로 구성된 기로부터 선택된 멤버이고, 이중 치환된 페닐은 할로, 저급알킬, 저급알킬옥시, 트리플루오로메틸, 니트로, 아미노 및 히드록시로 구성된 기로부터 각각 독자적으로 선택된 1 내지 3개의 치환체를 가지고 있다.Ar is aryl, which aryl is a member selected from the group consisting of phenyl, substituted phenyl, thienyl, furanyl and pyridinyl, and the double substituted phenyl is halo, lower alkyl, lower alkyloxy, trifluoromethyl, nitro, Each having 1 to 3 substituents independently selected from the group consisting of amino and hydroxy. R이 수소인 청구범위 1에 의한 화합물.A compound according to claim 1, wherein R is hydrogen. R이 수소이고, X가 >C=O, >C(O-저급알킬)2또는인 청구범위 1에 의한 화합물.R is hydrogen, X is> C = O,> C (O-lower alkyl) 2 or A compound according to claim 1. R이 수소이고, X가 >C=O이며 Alk가 1,2-에탄다이일 라디칼인 청구범위 1에 의한 화합물.A compound according to claim 1 wherein R is hydrogen, X is> C═O and Alk is a 1,2-ethanediyl radical. 3-[2-[4-(4-플루오로벤조일)-1-피페리딘일]에틸]-2-메틸-4H-피리도[1,2-a] 피리미딘-4-완과 이것의 약제로 사용 가능한 "산부가염"으로 구성된 기로부터 선택된 화합물.3- [2- [4- (4-fluorobenzoyl) -1-piperidinyl] ethyl] -2-methyl-4H-pyrido [1,2-a] pyrimidin-4-wan and its agents Compounds selected from the group consisting of "acid addition salts" usable as: 일반식,General Formula, 로 표시되는 4H-피리도[1,2-a] 피리미딘-4-완 유도체와 이것의 약제로 사용 가능한 "산부가염"으로 구성된 기로부터 선택된 화합물.A compound selected from the group consisting of 4H-pyrido [1,2-a] pyrimidine-4-wan derivatives represented by " acid addition salts " usable as medicaments thereof. 이 중에서 :among these : R1과 R2는 수소, 저급알킬, 저급알킬옥시, 할로 및 트리플루오로메틸로 구성된 기로부터 각각 독자적으로 선택된 것이다;R 1 and R 2 are each independently selected from the group consisting of hydrogen, lower alkyl, lower alkyloxy, halo and trifluoromethyl; R3는 수소, 저급알킬 및 아릴로 구성된 기로부터 선택된 멤버이며;R 3 is a member selected from the group consisting of hydrogen, lower alkyl and aryl; Alk는 저급알킬렌 라디칼이고;Alk is a lower alkylene radical; R는 피페리딘 고리의 2-, 3- 또는 4-위치에서 수소, 저급알킬, 히드록시, 저급알킬옥시, 히드록시메틸로 구성된 기로 부터 선택된 멤버이다; 그리고 R4와 R5는 수소, 할로, 저급알킬, 저급알킬옥시, 트리플루오로메틸, 니트로, 아미노 및 히드록시로 구성된 기로부터 각각 독자적으로 선택된 것이다;R is a member selected from the group consisting of hydrogen, lower alkyl, hydroxy, lower alkyloxy, hydroxymethyl at the 2-, 3- or 4- position of the piperidine ring; And R 4 and R 5 are each independently selected from the group consisting of hydrogen, halo, lower alkyl, lower alkyloxy, trifluoromethyl, nitro, amino and hydroxy; 상기중 언급된 아릴은 페닐, 치환된 페닐, 티에닐, 푸란일 및 피리딘일로 구성된 기로부터 선택된 멤버인데 상기의 치환된 페닐은 할로, 저급알킬, 저급알킬옥시, 트리플루오로메틸, 니트로, 아미노 및 히드록시로 구성된 기로부터 각각 독자적으로 선택된 1개 내지 3개의 치환체를 가지고 있다.The aforementioned aryl is a member selected from the group consisting of phenyl, substituted phenyl, thienyl, furanyl and pyridinyl, wherein substituted phenyl is halo, lower alkyl, lower alkyloxy, trifluoromethyl, nitro, amino and Each having 1 to 3 substituents independently selected from the group consisting of hydroxy. 일반식,General Formula, 로 표시되는 3-[(1-피페리디닐)알킬]-4H-피리도[1,2-a]-4-완 유도체와 이것의 약재로 사용가능한 "산부가염"으로 구성된 기로부터 선택된 화합물을 제조하는 방법, 이중에서 R1과 R2는 수소, 저급알킬, 저급알킬옥시, 할로 및 트리로플루오로메틸로 구성된 기로부터 각각 독자적으로 선택된 것이고;A compound selected from the group consisting of 3-[(1-piperidinyl) alkyl] -4H-pyrido [1,2-a] -4-wan derivatives represented by " acid addition salts " Process for preparation, wherein R 1 and R 2 are each independently selected from the group consisting of hydrogen, lower alkyl, lower alkyloxy, halo and trirofluoromethyl; R3는 수소, 저급알킬 및 아릴로 구성된 기로부터 선택된 멤버이며;R 3 is a member selected from the group consisting of hydrogen, lower alkyl and aryl; Alk는 저급알킬렌 라디칼이고;Alk is a lower alkylene radical; R는 피페리딘 고리의 2-, 3- 또는 4-위치에서 수소, 저급알킬, 히드록시, 저급알킬옥시 및 히드록시메틸로 구성된 기로부터 선택된 멤버이며;R is a member selected from the group consisting of hydrogen, lower alkyl, hydroxy, lower alkyloxy and hydroxymethyl at the 2-, 3- or 4- position of the piperidine ring; X는, X is >C=NOH 및 >C=N-NH2로 구성된 기로 부터 선택된 멤버인데, 이중 Ra는 수소 또는 저급알킬이고 q는 정수 2 또는 3이다; 그리고A member selected from the group consisting of> C = NOH and> C = N-NH 2 , wherein R a is hydrogen or lower alkyl and q is an integer 2 or 3; And Ar는 아릴인데, 아릴은 페닐, 치환된 페닐, 티에닐, 푸라닐 및 피리딘일로 구성된 기로부터 선택된 멤버이고, 이들중 치환된 페닐은 할로, 저급알킬, 저급알킬옥시, 트리플루오로메틸, 니트로, 아미노 및 히드록시로 구성된 기로 부터 각각 독자적으로 선택된 1개 내지 3개의 치환체를 가지고 있으며 다음과 같은 것들로 특정지워진다.Ar is aryl, where aryl is a member selected from the group consisting of phenyl, substituted phenyl, thienyl, furanyl and pyridinyl, of which substituted phenyl is halo, lower alkyl, lower alkyloxy, trifluoromethyl, nitro, It has 1 to 3 substituents each independently selected from the group consisting of amino and hydroxy and is characterized by the following. a) 일반식a) general formula 로 표시되는 화합물과,A compound represented by 일반식General formula 로 표시되는 화합물과의 반응.Reaction with the compound represented by. 이중 W는 할로 또는 술폰일옥시기와 같은 반응 에스테르를 나타내고, 이 반응은 적당한 반응-불활성 유기용대에서 적당한 염기의 첨가로 실행되며 반응혼합물의 환류온도에서는 더욱 잘 실행된다; 또는W represents a reactive ester such as a halo or sulfonyloxy group, which is carried out with the addition of a suitable base in a suitable reaction-inert organic solvent and better at the reflux temperature of the reaction mixture; or b) 일반식b) general formula 의 화합물의Of compounds 일반식,General Formula, 의 화합물과의 고리화.Cyclization with Compounds. 이중 반응물(Ⅳ)과 (Ⅴ)의 R1,R2,R3,Alk,X,R 및 Ar은 앞서 기술하였고 L은 저급알킬옥시, 히드록시, 할로, 아미노, 모노-또는 디(저급알킬) 아미노와 같은 적당한 이탈기를 나타내며, 상기 고리화반응은 적당한 반응-불활성 용매의 존재하에서, 더욱 좋게는 상승된 온도에서, 반응물들을 함께 교반함으로써 실행된다; 또는R 1 , R 2 , R 3 , Alk, X, R and Ar of the double reactants (IV) and (V) are described above and L is lower alkyloxy, hydroxy, halo, amino, mono- or di (lower alkyl). A) leaving a suitable leaving group such as amino, wherein the cyclization reaction is carried out by stirring the reactants together in the presence of a suitable reaction-inert solvent, more preferably at an elevated temperature; or c) i) 일반식,c) i) a general formula, 의 화합물의, 산성매질에서 일반식,Of the compounds of the general formula, 의 화합물을 가수분해 함에 의한 제조.By hydrolysis of a compound. 이중 R1,R2,R3,Alk 및 R은 앞서 정의한 바와 같고 R4와 R5는 수소, 할로저급알킬, 저급알킬옥시, 트리플루오로메틸, 니트로, 아미노 및 히드록시 구성된 기로부터 각각 독자적으로 선택된 것이다; 또는Wherein R 1 , R 2 , R 3 , Alk and R are as previously defined and R 4 and R 5 are each independently from the group consisting of hydrogen, haloloweralkyl, loweralkyloxy, trifluoromethyl, nitro, amino and hydroxy Is selected; or c) ii) 일반식,c) ii) a general formula, 의 화합물의 수소화붕소나트륨 또는 시아노수소화 붕소나트륨과 같은 적당한 환원제로 일반식,A suitable reducing agent such as sodium borohydride or sodium cyanoborohydride of the compound of 의 화합물의 환원에 의한 제조.Preparation by Reduction of Compounds. 이 경우에 수소화붕소나트륨을 환원제로 사용할 때 반응은 알칼리 수성매질에서, 더욱 좋게는 수용성유기용매와의 혼합물에서 실행된다; 또는In this case, when sodium borohydride is used as the reducing agent, the reaction is carried out in an alkaline aqueous medium, more preferably in a mixture with an aqueous organic solvent; or c) iii)c) iii) 의 화합물의 바람직하게는 저급알칸온산 및 할로겐화 아실 및 이것으로 부터의 무수화물 유도체를 사용하는 일반식(I -b)의 화합물의 아실화에 의한 제조; 또는Preparation by acylation of a compound of formula (I-b) using preferably lower alkanoic acid and halogenated acyl and anhydride derivatives thereof; or c) iv) 일반식,c) iv) a general formula, 의 화합물의 아연아말감 및 염산을 사용하는 클레멘센 환원 또는 높은 온도에서 끓는 극성 용매에서 히드라진 및 알칼리를 사용하는 볼프-키스너 환원과 같은 것에 의하는 일반식(I-c)의 화합물의 카르보닐기의 환원에 의한 제조; 또는By reduction of the carbonyl group of the compound of formula (Ic), such as by clemensen reduction using zinc amalgam and hydrochloric acid or by Wolf-Kisner reduction using hydrazine and alkali in boiling polar solvents at elevated temperatures Produce; or c) v) X가 >C(O-저급알킬) 또는이고, 이중 q가 앞서 기술된 것과 같은 일반식(Ⅰ)의 화합물은 대응하는 카르보닐 화합물로 부터 후자를 케탈화 반응시킴으로써 유도될 수 있다; 또는c) v) X is> C (O-lower alkyl) or Wherein q is a compound of formula (I), wherein q is described above, which can be derived from the corresponding carbonyl compound by ketalizing the latter; or c) vi) X가 일반식 <C=NOH의 라디칼 또는 일반식 >C=N-NH2의 라디칼을 나타내는 일반식(Ⅰ)의 화합물은 대응하는 카르보닐 화합물로 부터 후자를 염화수소 히드록실아민 또는 염화수소 히드라진과 각각 반응시킴으로써 유도될 수 있다; 또는c) vi) A compound of formula (I) in which X represents a radical of the formula <C = NOH or a radical of the formula> C = N-NH 2 , from the corresponding carbonyl compound, the latter being hydrogen chloride hydroxylamine or Can be induced by reacting with hydrogen hydrazine, respectively; or c) vii) 일반식c) vii) general formula 의 화합물, 일반식Of compounds, general formula 의 화합물의 포름알데히드 또는 이것의 유도체와의 반응에 의한 제조.Preparation of the compound by reaction with formaldehyde or derivative thereof. 상기 히드록시메틸화 반응은 출발화합물(I -g)를 적당한 염기의 존재하에서 적당한 극성용매에 넣어교반하고 가열함으로써 실행된다. 그리고, 원한다면, 상기 방법의 생성물의 약제로 사용 가능한 "산부가염"의 제조The hydroxymethylation reaction is carried out by stirring and heating the starting compound (I-g) in a suitable polar solvent in the presence of a suitable base. And, if desired, the preparation of "acid addition salts" which can be used as medicaments of the products of the process. 3-[2-[4-(4-플루오로벤조일)-1-피페리딘일]에틸-2-메틸-4H-피리도[1,2-a] 피리미딘-4-완과 이것의 약제로 사용 가능한 "산부가염"으로 구성된 기로부터 선택되고 3-(2-클로로에틸)-2-메틸-4H-피리도[1,2-a] 피리미딘-4-완의 (4-플루오로페닐)(4-피페리딘일) 메탄은 히드로클로리드와의 반응으로 특정지워지는 화합물의 제조방법 및 원한다면 이것의 생성물의 약제로 사용 가능한 "산부가염"의 제조방법.3- [2- [4- (4-fluorobenzoyl) -1-piperidinyl] ethyl-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-wan and its pharmaceuticals 3- (2-Chloroethyl) -2-methyl-4H-pyrido [1,2-a] pyrimidine-4-wan (4-fluorophenyl) selected from the group consisting of available "acid addition salts" (4-piperidinyl) A process for preparing compounds wherein methane is characterized by reaction with hydrochloride and for preparing "acid addition salts" which can be used as medicaments thereof if desired. 일반식,General Formula, 로 표시되는 4H-피리도[1,2-a] 피리미딘-4-완 유도체와 이것의 약제로 사용 가능한 "산부가염"으로 구성된 기로부터 선택된 화합물의 제조방법.A method for producing a compound selected from the group consisting of 4H-pyrido [1,2-a] pyrimidine-4-wan derivatives represented by " acid addition salts " usable as medicaments thereof. 이중에서 :among these : R1과 R2는 수소, 저급알킬, 저급알킬옥시, 할로 및 트리플루오로메틸로 구성된 기로부터 각각 독자적으로 선택된 것이며 :R 1 and R 2 are each independently selected from the group consisting of hydrogen, lower alkyl, lower alkyloxy, halo and trifluoromethyl: R3는 수소, 저급알킬 및 아릴로 구성된 기로부터 선택된 멤버이고;R 3 is a member selected from the group consisting of hydrogen, lower alkyl and aryl; Alk는 저급알킬렌 라디칼이며;Alk is a lower alkylene radical; R은 피페리딘 고리의 2-, 3- 또는 4-위치에서 수소, 저급알킬, 히드록시, 저급알킬옥시, 히드록시 메틸로 구성된 기로부터 선택된 멤버이다.R is a member selected from the group consisting of hydrogen, lower alkyl, hydroxy, lower alkyloxy, hydroxy methyl at the 2-, 3- or 4- position of the piperidine ring. 그리고 R4와 R5는 수소, 할로, 저급알킬, 저급알킬옥시, 트리플루오로메틸, 니트로, 아미노 및 히드록시로 구성된 기로부터 각각 독자적으로 선택된 것인데; 이 중 아릴은 페닐, 치환된 페닐, 티에닐, 푸란일 및 피리딘일로 구성된 기로부터 선택된 멤버이고, 상기 치환된 페닐은 할로, 저급알킬, 저급알킬옥시, 트리플루오로메틸, 니트로, 아미노 및 히드록시로 구성된 기로부터 각각 독자적으로 선택된 1개 내지 3개의 치환체를 가지고 있다.And R 4 and R 5 are each independently selected from the group consisting of hydrogen, halo, lower alkyl, lower alkyloxy, trifluoromethyl, nitro, amino and hydroxy; Aryl is a member selected from the group consisting of phenyl, substituted phenyl, thienyl, furanyl and pyridinyl, said substituted phenyl being halo, lower alkyl, lower alkyloxy, trifluoromethyl, nitro, amino and hydroxy Each having 1 to 3 substituents independently selected from the group consisting of 또한 상기 화합물은 일반식,In addition, the compound is a general formula, 의 화합물의 일반식,General formula of a compound of 의 화합물과의 반응으로 특정지워지는 데, 상기 식중 W는 할로 또는 술포닐옥시기와 같은 반응 에스테르기로 나타내며, 상기 반응은 적당한 반응-불활성 유기용매에서 적당한 염기의 첨가로 실행되는데 이 반응은 반응혼합물의 환류온도에서 더욱 잘 실행된다. 그리고 원한다면, 이 생성물의 약제로 사용가능한 산부가염의 제조방법.Characterized by reaction with a compound of, wherein W is represented by a reactive ester group such as halo or sulfonyloxy group, the reaction being carried out by addition of a suitable base in a suitable reaction-inert organic solvent, the reaction of the reaction mixture It performs better at reflux temperature. And, if desired, a process for preparing acid addition salts which can be used as a medicament of this product. 일반식(Ⅰ)의 화합물의 세라토닌-길항물질로서의 사용.Use of a compound of formula (I) as a seratonin-antagonist. 유효성분 및 약제로 사용 가능한 담체로서 일반식(Ⅰ)의 화합물을 함유한 세라토닌-길항물질.A seratonin-antagonist containing a compound of formula (I) as a carrier usable as an active ingredient and a medicament. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019810001233A 1980-03-28 1981-04-11 Process for preparing 3-(1-piperidinylalkyl)-4h-pyrido(1,2-a)pyrimidine-4-one derivatives KR850000412B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019840005210A KR850000413B1 (en) 1980-03-28 1984-08-27 Process for preparing 3-(1-piperidinylalkyl)-4h-pyrido(1,2-a)pyrimidine-4-one derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13484580A 1980-03-28 1980-03-28
US134,845 1980-03-28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1019840005210A Division KR850000413B1 (en) 1980-03-28 1984-08-27 Process for preparing 3-(1-piperidinylalkyl)-4h-pyrido(1,2-a)pyrimidine-4-one derivatives

Publications (2)

Publication Number Publication Date
KR830005220A true KR830005220A (en) 1983-08-03
KR850000412B1 KR850000412B1 (en) 1985-03-26

Family

ID=22465278

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1019810001233A KR850000412B1 (en) 1980-03-28 1981-04-11 Process for preparing 3-(1-piperidinylalkyl)-4h-pyrido(1,2-a)pyrimidine-4-one derivatives
KR1019840005210A KR850000413B1 (en) 1980-03-28 1984-08-27 Process for preparing 3-(1-piperidinylalkyl)-4h-pyrido(1,2-a)pyrimidine-4-one derivatives

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1019840005210A KR850000413B1 (en) 1980-03-28 1984-08-27 Process for preparing 3-(1-piperidinylalkyl)-4h-pyrido(1,2-a)pyrimidine-4-one derivatives

Country Status (5)

Country Link
JP (1) JPS56150091A (en)
KR (2) KR850000412B1 (en)
PL (2) PL132428B1 (en)
SU (1) SU1093251A3 (en)
ZA (1) ZA812085B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0615529B2 (en) * 1985-04-01 1994-03-02 エーザイ株式会社 Novel piperidine derivative
EP0335442B1 (en) * 1988-03-28 1996-05-15 Janssen Pharmaceutica N.V. Agents for preserving or restoring the soundness of the skin
ES2842289T3 (en) * 2008-02-29 2021-07-13 Vm Therapeutics Llc Compounds to treat pain syndrome and other disorders
JP6092897B2 (en) 2012-02-10 2017-03-08 ピーティーシー セラピューティクス, インコーポレイテッド Compounds for treating spinal muscular atrophy
WO2016196386A1 (en) 2015-05-30 2016-12-08 Ptc Therapeutics, Inc. Methods for modulating rna splicing
SI3386511T1 (en) 2015-12-10 2021-09-30 Ptc Therapeutics, Inc. Methods for treating huntington's disease
AU2017363369A1 (en) 2016-11-28 2019-05-30 Ptc Therapeutics, Inc Methods for modulating RNA splicing
EA201992878A1 (en) 2017-06-05 2020-05-08 ПиТиСи ТЕРАПЬЮТИКС, ИНК. COMPOUNDS FOR TREATMENT OF HUNTINGTON'S DISEASE
AU2018284853A1 (en) 2017-06-14 2019-12-19 Ptc Therapeutics, Inc. Methods for modifying RNA splicing
BR112019027717A2 (en) 2017-06-28 2020-07-28 Ptc Therapeutics, Inc. methods to treat huntington's disease
US11395822B2 (en) 2017-06-28 2022-07-26 Ptc Therapeutics, Inc. Methods for treating Huntington's disease
CA3094703A1 (en) 2018-03-27 2019-10-03 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
WO2020005873A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating huntington's disease
US11685746B2 (en) 2018-06-27 2023-06-27 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease

Also Published As

Publication number Publication date
PL230364A1 (en) 1982-03-29
SU1093251A3 (en) 1984-05-15
ZA812085B (en) 1982-11-24
JPS56150091A (en) 1981-11-20
KR850000413B1 (en) 1985-03-26
KR850000412B1 (en) 1985-03-26
PL233902A1 (en) 1982-07-19
JPH0215550B2 (en) 1990-04-12
PL131162B1 (en) 1984-10-31
PL132428B1 (en) 1985-03-30

Similar Documents

Publication Publication Date Title
KR830005220A (en) Preparation of new 3- (1-piperidinylalkyl) -4H-pyrido [1,2-a] pyrimidin-4-wan derivatives
RU2062776C1 (en) Method for production of substituted n-(aryl oxyalkyl)-heteroaryl piperidine or heteroaryl piperazine
EP0040639B1 (en) Isoxazole derivatives
JPH0692403B2 (en) Novel benzisoxazole derivative and pharmaceutical composition containing the derivative
US3980658A (en) (Indolyl-piperidino or -1,2,5,6-tetrahydro-pyridyl)-p-fluoro-butyrophenones and salts thereof
YU48020B (en) PROCEDURE FOR OBTAINING NEW PHARMACOLOGICAL ACTIVE KETHOL DERIVATIVES
NO20004624L (en) Benzenesulfonamide derivatives and their use as drugs
HUP9904125A2 (en) 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives as tachykinin receptor antagonists
JPS63290874A (en) Manufacture of 1,4-dihydropyridinecarboxylic acid compound
CS556587A2 (en) Process for preparing aminoderivatives
KR920019746A (en) Novel cyclohexylbenzamide derivatives, methods for their preparation and use as medicaments
KR850007596A (en) Method for preparing 1,4-dihydro-4-oxonaphthyridine derivative
KR910018380A (en) New 2,9-disubstituted-4H-pyrido [1,2-a] pyrimidin-4-ones
KR880011147A (en) Triazolone derivatives
CA2007127A1 (en) Piperidines, process for their preparation and drugs containing same
US3511847A (en) 2,6-di-lower alkyl - 1,4-dihydro - 4-(2-trifluoromethylphenyl) - 3,5 - pyridinedicarboxylic acid esters
SE7710873L (en) NEW 1H-PYRAZOLO (3,4-B) PYRIDINES
AU685881B2 (en) 5-heteroarylindole derivatives as benzodiazepine receptor site agonists and antagonists
CZ422499A3 (en) Process for preparing isoxazolidinedione compounds
US3489769A (en) 1-substituted-3-aroyl-pyrrolidines
IL83367A (en) 3-aryl-3-cycloalkyl-piperidine-2,6-dione derivatives,their preparation and pharmaceutical compositions containing them
RU95101859A (en) PROCESS FOR PREPARING 3-(2-[6-FLYOROBENZO [d] ISOXAZOL-3-YL) PIPERIDIN-1-YL) ETHYL-2-METHYL-6,7,8,9-TETRAHYDRO-4-PYRIDO [1,2-a] PYRIMIDIN-4-4-ONE AND INTERMEDIATE PRODUCTS FOR PREPARATION THEREOF
EP0220917B1 (en) 1,4-dihydropyridine pharmaceutical derivatives and their salts, and the preparation thereof
US4187379A (en) 3-Aryloxy-2-pyridinecarbonitrile 1-oxide compounds
US3850940A (en) Intermediate pyrazolopyridine carbonitriles